Foghorn Therapeutics, Inc. (FHTX)
1.87
-0.04
(-1.84%)
USD |
NASDAQ |
Nov 06, 16:00
1.865
0.00 (0.00%)
After-Hours: 20:00
Foghorn Therapeutics Research and Development Expense (Annual) : 82.13M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 82.13M |
| December 31, 2024 | 91.41M |
| December 31, 2023 | 106.24M |
| December 31, 2022 | 102.30M |
| Date | Value |
|---|---|
| December 31, 2021 | 77.10M |
| December 31, 2020 | 56.39M |
| December 31, 2019 | 44.36M |
| December 31, 2018 | 21.22M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Anavex Life Sciences Corp. | 37.59M |
| Vaxcyte, Inc. | 794.31M |
| Connect Biopharma Holdings Ltd. | 37.80M |
| Caribou Biosciences, Inc. | 109.44M |
| Arrowhead Pharmaceuticals, Inc. | 585.26M |